| Bioactivity | Dazopride is an antiemetic agent. |
| In Vivo | Dazopride (0.3 mg/kg) produces significant enhancement of gastric evacuation and is approximately six times more potent than metoclopramide in gastric evacuation assay. Dazopride (0.3-10.0 mg/kg, i.v.) produces a dose-related increase in antral motility primarily by increasing the amplitude of antral contractions in three conscious dogs. Dazopride significantly reduces the emetic frequency from that of the control group[1]. Dazopride (5 mg/kg, i.p.) antagonises the tetralin-induced emesis in all animals, but fails to antagonise the response at 0.25-2.5 mg/kg. Dazopride fails to modify cisplatin-induced emesis at 0.1 mg/kg (i.v,) although a larger dose of 1.0 mg/kg abolishes or attenuates the response and 5.0 mg/kg of dazopride antagonises the development ofemesis in all animals[2]. |
| Name | Dazopride |
| CAS | 70181-03-2 |
| Formula | C15H23ClN4O2 |
| Molar Mass | 326.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alphin RS, et al. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. Dig Dis Sci. 1986 May;31(5):524-9. [2]. Costall B, et al. The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology. 1987 Jul;26(7A):669-77. |